41230-93-7

Basic information

• Product Name: 5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE
• Synonyms: 5-bromo-4-methyl-2,3-Pyridinediamine;2,3-diamino-5-bromo-4-methylpyridine;5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE;5-Bromo-2,3-diamino-4-methylpyridine;5-broMo-4-Methylpyridine-2
• CAS NO: 41230-93-7
• Molecular Formula: C₆H₈BrN₃
• Molecular Weight: 202.05
• EINECS: 145-896-5
• Product Categories: Heterocycle-Pyridine series
• Mol File: 41230-93-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 161-162℃
• Boiling Point: 331.221 °C at 760 mmHg
• Flash Point: 154.118 °C
• Appearance: /
• Density: 1.688 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.16±0.50(Predicted)
• CAS DataBase Reference: 5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE(41230-93-7)
• EPA Substance Registry System: 5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE(41230-93-7)

Safety Data

• Hazardous Substances Data: 41230-93-7(Hazardous Substances Data)

Usage

General Description

5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE is a chemical compound with the molecular formula C7H8BrN3. It is an organic compound that belongs to the class of pyridine derivatives. 5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has potential applications in the development of anticancer drugs and the treatment of various diseases. 5-BROMO-4-METHYL-PYRIDINE-2,3-DIAMINE is considered to be a valuable intermediate in organic synthesis due to its versatile reactivity and potential for producing valuable compounds with biological activity.

InChI:InChI=1/C6H8BrN3/c1-3-4(7)2-10-6(9)5(3)8/h2H,8H2,1H3,(H2,9,10)

Upstream product

• 100367-40-6 2-amino-3-nitro-4-methyl-5-bromopyridine 
• 695-34-1 2-Amino-4-methylpyridine 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 923929-10-6 5-bromo-2-nitramino-4-picoline 

Downstream Products

• 116035-72-4 6-bromo-7-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one 
• 120640-83-7 6-bromo-7-methyl-1H-[1,2,3]triazolo[4,5-b]pyridine 
• 662117-41-1 6-bromo-7-methyl-2-(4-nitrophenyl)-1H-imidazo[4,5-b]pyridine 
• 662117-40-0 6-bromo-7-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine 
• 116605-69-7 7-bromo-8-methylpyrido[2,3-b]pyrazine 

Relevant articles and documents

Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis

The histamine H4 receptor (H4R), a member of the G-protein coupled receptor family, has been considered as a potential therapeutic target for treating atopic dermatitis (AD). A large number of H4R antagonists have been disclosed, but no efficient agents controlling both pruritus and inflammation in AD have been developed yet. Here, we have discovered a novel class of orally available H4R antagonists showing strong anti-itching and anti-inflammation activity as well as excellent selectivity against off-targets. A pharmacophore-based virtual screening system constructed in-house successfully identified initial hit compound 9, and the subsequent homology model-guided optimization efficiently led us to discover pyrido[2,3-e]tetrazolo[1,5-a]pyrazine analogue 48 as a novel chemotype of a potent and highly selective H4R antagonist. Importantly, orally administered compound 48 exhibits remarkable efficacy on antipruritus and anti-inflammation with a favorable pharmacokinetic (PK) profile in several mouse models of AD. Thus, these data strongly suggest that our compound 48 is a promising clinical candidate for treatment of AD.

NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES

The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.

Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses

Bioisosteric deaza analogues of 6-methyl-9-β-d-ribofuranosylpurine, a hydrophobic analogue of adenosine, were synthesized and evaluated for antiviral activity. Whereas the 1-deaza and 3-deaza analogues were essentially inactive in plaque assays of infectivity, a novel 7-deaza-6-methyl-9-β-d- ribofuranosylpurine analogue, structurally related to the natural product tubercidin, potently inhibited replication of poliovirus (PV) in HeLa cells (IC50 = 11 nM) and dengue virus (DENV) in Vero cells (IC50 = 62 nM). Selectivity against PV over cytotoxic effects to HeLa cells was >100-fold after incubation for 7 h. Mechanistic studies of the 5′-triphosphate of 7-deaza-6-methyl-9-β-d-ribofuranosylpurine revealed that this compound is an efficient substrate of PV RNA-dependent RNA polymerase (RdRP) and is incorporated into RNA mimicking both ATP and GTP.